The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor

A Crilly, I.B. McInnes, H.A. Capell, R. Madhok

Research output: Contribution to journalArticle

Abstract

Cytokine pathways are central to the perpetuation of synovial inflammation in rheumatoid arthritis (RA). Azathioprine (AZA) has disease modifying activity in RA. This study addressed the effect of AZA on serum IL-6 and soluble IL-2 receptor (sIL-2R) levels in RA. Over a 24 week period of therapy significant clinical improvement was observed. However, serum levels of both IL-6 and soluble IL-2R levels did not significantly change after AZA therapy. AZA therapy did not significantly alter the peripheral blood monocytes ability to produce IL-6 in vitro, either in the presence or absence of LPS. The mechanism by which AZA achieves clinical improvement in RA patients does not appear to be through IL-6 modulation or modification of synovial lymphocyte activation as assessed by serum sIL-2R levels.

Original languageEnglish
Pages (from-to)87-91
Number of pages5
JournalScandinavian Journal of Rheumatology
Volume23
Issue number2
DOIs
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Interleukin-2 Receptors
Azathioprine
Interleukin-6
Rheumatoid Arthritis
Serum
Lymphocyte Activation
Monocytes
Therapeutics
Cytokines
Inflammation

Keywords

  • Adult
  • Aged
  • Arthritis, Rheumatoid
  • Azathioprine
  • Cohort Studies
  • Female
  • Humans
  • Interleukin-6
  • Male
  • Middle Aged
  • Receptors, Interleukin-2
  • Solubility

Cite this

@article{614849f20f2244a1aa70d16d393e7b25,
title = "The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor",
abstract = "Cytokine pathways are central to the perpetuation of synovial inflammation in rheumatoid arthritis (RA). Azathioprine (AZA) has disease modifying activity in RA. This study addressed the effect of AZA on serum IL-6 and soluble IL-2 receptor (sIL-2R) levels in RA. Over a 24 week period of therapy significant clinical improvement was observed. However, serum levels of both IL-6 and soluble IL-2R levels did not significantly change after AZA therapy. AZA therapy did not significantly alter the peripheral blood monocytes ability to produce IL-6 in vitro, either in the presence or absence of LPS. The mechanism by which AZA achieves clinical improvement in RA patients does not appear to be through IL-6 modulation or modification of synovial lymphocyte activation as assessed by serum sIL-2R levels.",
keywords = "Adult, Aged, Arthritis, Rheumatoid, Azathioprine, Cohort Studies, Female, Humans, Interleukin-6, Male, Middle Aged, Receptors, Interleukin-2, Solubility",
author = "A Crilly and I.B. McInnes and H.A. Capell and R. Madhok",
year = "1994",
doi = "10.3109/03009749409103034",
language = "English",
volume = "23",
pages = "87--91",
journal = "Scandinavian Journal of Rheumatology",
issn = "0300-9742",
publisher = "Informa Healthcare",
number = "2",

}

The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor. / Crilly, A; McInnes, I.B.; Capell, H.A.; Madhok, R.

In: Scandinavian Journal of Rheumatology, Vol. 23, No. 2, 1994, p. 87-91.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor

AU - Crilly, A

AU - McInnes, I.B.

AU - Capell, H.A.

AU - Madhok, R.

PY - 1994

Y1 - 1994

N2 - Cytokine pathways are central to the perpetuation of synovial inflammation in rheumatoid arthritis (RA). Azathioprine (AZA) has disease modifying activity in RA. This study addressed the effect of AZA on serum IL-6 and soluble IL-2 receptor (sIL-2R) levels in RA. Over a 24 week period of therapy significant clinical improvement was observed. However, serum levels of both IL-6 and soluble IL-2R levels did not significantly change after AZA therapy. AZA therapy did not significantly alter the peripheral blood monocytes ability to produce IL-6 in vitro, either in the presence or absence of LPS. The mechanism by which AZA achieves clinical improvement in RA patients does not appear to be through IL-6 modulation or modification of synovial lymphocyte activation as assessed by serum sIL-2R levels.

AB - Cytokine pathways are central to the perpetuation of synovial inflammation in rheumatoid arthritis (RA). Azathioprine (AZA) has disease modifying activity in RA. This study addressed the effect of AZA on serum IL-6 and soluble IL-2 receptor (sIL-2R) levels in RA. Over a 24 week period of therapy significant clinical improvement was observed. However, serum levels of both IL-6 and soluble IL-2R levels did not significantly change after AZA therapy. AZA therapy did not significantly alter the peripheral blood monocytes ability to produce IL-6 in vitro, either in the presence or absence of LPS. The mechanism by which AZA achieves clinical improvement in RA patients does not appear to be through IL-6 modulation or modification of synovial lymphocyte activation as assessed by serum sIL-2R levels.

KW - Adult

KW - Aged

KW - Arthritis, Rheumatoid

KW - Azathioprine

KW - Cohort Studies

KW - Female

KW - Humans

KW - Interleukin-6

KW - Male

KW - Middle Aged

KW - Receptors, Interleukin-2

KW - Solubility

U2 - 10.3109/03009749409103034

DO - 10.3109/03009749409103034

M3 - Article

VL - 23

SP - 87

EP - 91

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

SN - 0300-9742

IS - 2

ER -